Peripheral stem cells were mobilized and collected in 26 pediatric patients with malignant diseases. A total of 47 leukaphereses were performed in the 26 patients. The mean number of nucleated cells collected was 4.5 ؎ 2.6 × 10 8 /kg and the number of CD34 ؉ progenitors collected was 6.7 ؎ 6.8 × 10 6 /kg. CD34-positive selection was performed using a two-step method of magnetic-activated cell sorting (MACS) in 24 patients or a combination of an immunoaffinity column and MACS in two patients. The purity of the positively selected CD34
engraftment, 3 and the ability of PBSC to provide long-term hematopoietic reconstitution seems to be equivalent to bone marrow. 4 Therefore, an increased number of patients with solid tumors or hematological diseases are reconstituted with PBSC after myeloablative therapy. 5 One of the original arguments for the use of PBSC rather than bone marrow was the assumption that peripheral blood contains fewer contaminating tumor cells than the corresponding bone marrow. 6 However, the development of sensitive methods for the detection of tumor cells clearly demonstrates that contamination of peripheral blood with malignant cells is common. 7 Additionally, gene marking experiments in patients with leukemia and neuroblastoma have clearly documented that relapses after bone marrow transplantation can originate from tumor cells contaminating the cryopreserved bone marrow. [8] [9] [10] In order to reduce the number of tumor cells in PBSC prior to reinfusion, positive selection of peripheral CD34 + progenitor cells has been introduced in CD34-negative malignancies. [11] [12] [13] This offers the possibility of depleting tumor cells which show a heterogenous expression of tumor-associated antigens and might not therefore be suitable for a negative depletion strategy with antibodies against these tumor antigens. However, in order to obtain an effective tumor cell depletion, the purity of the positively selected CD34 + progenitors must be as high as possible. A recently described laboratory scale method which is able to obtain very high purities with good recoveries is magnetic-activated cell sorting (MACS). 14, 15 The magnetic microbeads used in this method are 50-100 nm in size and, after positive selection, remain on the surface of the progenitor cells without affecting their biological function in vitro.
In this paper we show that, by modifying this method to a large-scale version, autologous peripheral CD34 + progenitor cells can be highly purified in the clinical setting with an excellent recovery and that reinfusion of these cells after myeloablative therapy results in a rapid, complete and sustained reconstitution of hematopoiesis.
Patients and methods

Patients
Peripheral CD34
+ progenitors were collected and isolated in 26 pediatric patients with malignant dieseases (one large anaplastic lymphoma (relapse), three B cell leukemia/ lymphoma, one Hodgkin's lymphoma (relapse) and 21 neuroblastoma stage 4). The age and the body weight of the patients ranged from 1 to 16 years and 8 to 50 kg, respectively. Informed consent was given from the parents for the procedure.
Peripheral stem cell mobilization and collection
Stem cells were mobilized either with a single 1-h infusion of cyclophosphamide (4 g/m 2 ) or with a cytostatic regimen which was part of the therapy protocol for the underlying disease. Both regimens were followed by the daily subcutaneous application of G-CSF (Neupogen; Amgen, Munich, Germany) at a dose of 10 g/kg/day. Leukaphereses were started during the hematopoietic recovery phase using a Fenwall CS 3000 cell separator (Baxter, Munich, Germany) as described [16] [17] [18] or a Cobe Spectra (Cobe Laboratories, Lakewood, CO, USA).
Isolation of CD34
+ cells
In 21 patients, CD34
+ cells from the leukaphereses were isolated using the large scale SuperMacs system (Miltenyi Biotec, Bergisch-Gladbach, Germany) followed by the laboratory scale VarioMacs system (Miltenyi) or followed by a second SuperMacs column. In three patients with lower numbers of collected PBSCs, the capacity of the laboratory scale system was sufficient for the isolation of the CD34 + progenitors.
In two patients with high numbers of collected PBSCs, CD34
+ cells were pre-enriched using the CellPro immunoaffinity column (CellPro, Munich, Germany) followed by the laboratory scale VarioMacs system. The MACS separation technique was performed according to the manufacturer with some modifications. Briefly, cells from the leukaphereses were washed once and resuspended at a concentration of 2 × 10 8 cells/ml in cold separation buffer consisting of phosphate-buffered saline without calcium and magnesium (PBS − ) supplemented with 0.5% human serum albumin and 5 mM ethylenaminetetraacetic acid (EDTA; Sigma, Deisenhofen, Germany). The cells were then incubated with an anti-CD34 antibody (Miltenyi) for 30 min at 4°C, washed once and further incubated for 30 min with sheep anti-mouse antibody conjugated to the microbeads (Miltenyi) (15 patients). In 11 patients, an anti-CD34 antibody directly conjugated to microbeads was used (Miltenyi) . Cells were washed once and run through the SuperMacs column. The retained cells were eluted after removing the column from the magnet and run either through another SuperMacs column or through a VarioMacs system without further manipulation. The retained cells were eluted after removing the column out of the magnetic field and cryopreserved. In two patients, the CellPropre-enriched CD34 + cells were stained with the microbeads as described above and run directly through the VarioMacs column. A back-up of at least 1 × 10 8 /kg unmanipulated nucleated cells was cryopreserved in each patient.
Analysis of CD34
+ cells by flow cytometry
In order to determine the number of CD34 + cells prior to and after positive selection, cells from the leukaphereses were stained with the anti-CD34 antibody HPCA2 conjugated to phycoerythricin (Becton Dickinson, Heidelberg, Germany) and analyzed using flow cytometry (FACScalibur; Becton Dickinson). Nongranulated (low SSC) cells were counted after initial live gate-dependent exclusion of erythrocytes, platelets, subcellular particles, cell aggregates and debris (Milan/Mulhouse procedure). 19 In most of the patients, a clear CD34
+ population was seen in the flow cytometric analysis and the number of CD34 + cells was determined prior to the positive selection. In some of the patients, however, we were not able to accurately determine the number of the CD34 + cells prior to isolation due to their low numbers in the whole starting cell population. After positive selection, however, the number of CD34 + cells could be accurately determined due to their high purity.
Myeloablative therapy
Twenty-two patients each received myeloablative therapy according to their disease. Ten of the neuroblastoma patients additionally received high-dose therapy with 131-meta-Iodobenzylguanidine as described. 20 For reinfusion, CD34
+ cells were rapidly thawed and reinjected without further manipulation. All patients received G-CSF (Neupogen) at 10 g/kg/day as a continuous infusion from day +1 until a stable leukocyte count (Ͼ1 × 10 9 /l at 3 consecutive days) was reached. Supportive treatment included ondansetrone, parenteral nutrition, prophylactic oral antibiotics, fluconazol and acyclovir.
Analysis of immunoreconstitution after high-dose therapy
The lymphocyte subsets of 10 patients after ablative therapy were repeatedly analyzed by flow cytometry after hematopoietic reconstitution. Whole anticoagulated blood was therefore incubated with fluorescence-labeled anti-CD3, anti-CD19 and anti-CD56 (Becton Dickinson). Erythrocytes were lysed and a gate was set on the lymphocytes using the forward/side scatter characteristics of the cells and the absolute number of the lymphocytes was counted.
Results
Isolation and characterization of peripheral CD34
+ progenitors
CD34
+ cells from a single or from pooled leukaphereses were isolated using the MACS system alone in 24 patients and a combination of the CellPro method and the MACS system was used in two patients. In seven patients, one leukapheresis was sufficient to collect a target cell number of Ͼ1 × 10 6 /kg CD34 + cells for starting the isolation procedure. In 18 patients, two leukaphereses were necessary. In these patients, the cells from the first leukapheresis were stored overnight at 4°C in a refrigerator and pooled on the next day with the second leukapheresis. In one patient, two mobilization cycles with two leukaphereses per cycle had to be performed.
The mean number of processed cells was 4.5 Ϯ + cells was 93 Ϯ 10%. These data are summarized in Table 1 .
The isolation procedure using the magnetic microbeads does not interfere with the morphology of the isolated cells, since the microbeads are not visible using conventional light microscopy (data not shown). In Figure 1 , the ultrastructure of the cells is shown at a magnification of 25 000. The microbeads can clearly be seen on the surface of the CD34 + cells.
Flow cytometric analysis of isolated CD34 + cells
In Figure 2 , a representative example of a flow cytometric analysis of the isolated CD34 + progenitors is shown. Due to their size, the microbeads do not interfere with the light scatter characteristics in the analysis, since no change in the forward and light scatter behaviour was seen (Figure 2a) . In Figure 2b , a representative result of the fluorescence analysis of the isotype control and the isolated CD34 + cells is shown. Further analysis of this highly purified CD34
+ population showed the absence of mature T and B lymphocytes (Figure 2c ). Double-staining with anti-CD34 and anti-C19 shows that the small percentage of CD19 + cells seen in most samples comes from the coexpression of CD19 on a small subset of peripheral CD34 + progenitors (data not shown).
Hematopoietic reconstitution after myeloablative therapy
Myeloablative therapy was administered in 22 patients followed by infusion of MACS-separated CD34
+ progenitors. The conditioning regimen was chosen according to the underlying disease of the patient. All 22 patients received exclusively the peripheral CD34 + cells isolated by MACS. In all of the patients, a rapid hematopoietic recovery was observed with 12.4 Ϯ 2.7 days (range 8-19 days) to reach 0.5 × 10 9 neutrophils/l. The time to reach independence from platelet transfusion was 31.6 Ϯ 17.0 days (range 16-78 days). No transplant-related death was observed and in none of the patients was reinfusion of the unmanipulated back-up stem cells necessary. Two patients with neuroblastoma stage 4 died due to tumor progression and 20 patients are alive with the longest follow-up of Ͼ20 months. These results are summarized in Table 2 . Most of the patients with neuroblastoma are being or have been treated with a further adjuvant immunotherapy using the chimeric anti-disialoganglioside antibody ch 14.18 as described. 21 
Immunoreconstitution after high-dose therapy
Despite the fact that highly purified CD34
+ cells completely depleted of T and B lymphocytes were used for hematopoietic reconstitution, there was no delay in the recovery of these lymphocyte subsets after high-dose therapy. After 2-3 months, the absolute count of the lymphocyte subsets was in the subnormal or normal range with further increase during the following months (Figure 3) . Additionally, none of the patients experienced a severe infection in the posttransplant course.
Discussion
Positive selection of autologous CD34
+ hematopoietic progenitors from bone marrow or mobilized peripheral stem cells offers the possibility of purging in CD34-negative malignancies. However, in order to obtain a high purging efficiency, it is important to isolate the CD34 + cells as purely as possible. A purity of 99% CD34
+ progenitors translates into a tumor cell depletion of at least 4 logs in CD34-negative malignancies. Therefore, we were interested to establish a method for the clinical setting, which is able to reproducibly give such high purities of CD34 + progenitor cells. Methods, already described such as the immunadsorption method 11, 12 or the immunobeads method, 13 are able to enrich CD34 + cells especially in those patients with high numbers of CD34 + cells prior to positive selection, but might be less effective in those patients with a lower CD34 + starting population. In our previous experience, using an immunoaffinity device in 20 pediatric patients with neuroblastoma, the purity and recovery of peripheral autologous CD34
+ cells was 42 and 36%, respectively. 22 The poor recovery in these pediatric patients translates into an increased number of leukaphereses needed in order to collect a safe number of CD34 + cells for hematopoietic reconstitution. Especially in children with low body weight, the number of leukaphereses to be performed is an important factor. Therefore, we have been looking for methods which result in both a high purity and recovery of the CD34 + cells. In comparative laboratory scale experiments, the MACS method showed a high enrichment of CD34 + cells with a very good recovery of Ͼ90%. 23 Recently, a closed and semi-automated system has been described using this methodology with good purity and recovery. 24 However, we further optimized this method for the large scale purification of peripheral CD34 + cells. In 22 patients, we preenriched the CD34 + cells in a first step using the large scale Supermacs system either twice or followed by the final step using the laboratory scale VarioMacs system. In two patients with lower starting cell numbers, the capacity of this system was sufficient to perform a single step isolation. In two patients with very high starting cell numbers, the immunoaffinity method (CellPro) was used to pre-enrich the CD34 + cells followed by the isolation step using the laboratory scale MACS system. By using these procedures, the purity of the CD34 + cells was extremely high (98.8 Ϯ 0.7%) with an excellent recovery of 93 Ϯ 10% in
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+ cells R Handgretinger et al 991 Table 2 Hematopoietic engraftment after high-dose chemotherapy and follow-up of patients all 26 patients. Due to this high recovery, only 47 leukaphereses had to be performed in the 26 patients. Since we did not use an automated device, it was possible to adjust the cell separation procedure to the processed cell numbers. This approach resulted in a high purity and recovery of the target cell population. Even in patients with a low number of CD34 + cells in the starting population (Ͻ0.2%), a very high purity and recovery could be obtained. In these patients, it was difficult to measure accurately the absolute number of CD34 + cells prior to positive selection. The inaccuracy of determining low numbers of CD34 + cells is reflected by the wide range of the percentage of recovery. A recovery of Ͼ100% means that the CD34 + starting cell number was not accurately measured and that the number of CD34
+ cells in the starting population was underestimated by FACS analysis. However, no standardized methods have yet been introduced which might be able to solve the problem of CD34 enumeration. 25 High-dose myeloablative chemo/radiotherapy was performed in 22 children. In all patients, a complete and sustained hematological reconstitution was observed with the longest follow-up of 20 months. A complete reconstitution also occurred in the eight patients who received lower numbers of CD34 + cells (0.8-2.0 × 10 6 /kg). We have recently successfully grafted a patient with neuroblastoma with 0.5 × 10 6 /kg isolated CD34 + cells (unpublished results). Although this was associated with a prolonged hematopoietic recovery (Ͼ1000 neutrophils at day +35), we estimate from these results a lower threshold number of 0.5-1 × 10 6 /kg purified CD34
+ cells for engraftment in our setting. Such cell numbers can be obtained even in patients who poorly mobilize CD34 + progenitors and would otherwise not be eligible for autologous transplantation. Some patients showed a delayed recovery of the platelets although they were grafted with high numbers of CD34 + cells. All of these patients had very intensive chemotherapy prior to high-dose chemotherapy and this observation most likely reflects a certain damage to the bone marrow before the myeloablative therapy. Overall, however, the hematopoietic recovery after transplantation of CD34 + cells isolated with the MACS technique was similar to our previous experience in pediatric patients using unmanipulated PBSC 16 or positively selected CD34 + cells using the CellPro device. 22 The presence of microbeads at the surface of the CD34 + cells does not seem to have any negative impact on hematopoietic recovery nor does it induce long-term side-effects in patients and no attempts were made to remove the microbeads prior to reinfusion of the cells. Our hematopoietic recovery data indicate that there is no interference of the microbeads with the homing of the reinfused CD34 + cells to the bone marrow or with the capacity of the cells to a complete and sustained hematopoietic recovery. Additionally, there is no negative impact of the use of MACS-selected highly purified CD34 + cells on the immunological reconstitution of the patients after myeloablative therapy, since a normal and complete immunological reconstitution was observed in all patients. The speed of the immunological reconstitution observed in our patients was very similar to the reconstitution pattern observed in patients who had been transplanted with autologous unmanipulated PBSC. 26 Since our isolation procedure is associated with a nearly complete depletion of mature T and B lymphocytes (Figure 2c ), this method could be used in the treatment of autoimmune diseases such as multiple sclerosis in order to eliminate mature autoreactive lymphocytes by a myeloablative or immunoablative therapy followed by reconstitution with highly purified autologous CD34
+ cells which could result in the development of lymphocytes tolerant for the autoantigen. 27 The method can also be used in allogenic transplantation of peripheral mobilized stem cells as an effective T cell depletion method. To this end, we have successfully used haploidentical peripheral CD34
+ progenitor cells enriched with the same method for hematological reconstitution after myeloablative therapy in children without significant acute or chronic graft-versus-host disease. 28 In summary, we describe an effective and reproducible method for the clinical scale isolation of highly purified autologous CD34
+ progenitor cells. Reinfusion of these cells results in rapid hematological reconstitution after myeloablative therapy. In addition to the tumor purging effect obtained through the isolation of pure CD34
+ populations, the resulting highly effective T and B cell depletion offers the use of these cells in the treatment of autoimmune diseases and in allogeneic mismatched stem cell transplantation.
